Structure Therapeutics Inc.’s shares rose after more data on the company’s experimental weight-loss pill showed it’s shaping up to rival new oral treatments from Novo Nordisk A/S and Eli Lilly & Co.

Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial. The biotech is planning to launch a late-stage program for the drug later ...

Running Amazon just dropped the price on some of the most popular Asics running shoes — 3 pairs I'd add to my cart right now Running Hoka, Asics and Nike are slashing prices on running shoes — 29 ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics. The agreement grants Roche and ...

A thick layer of more than 12 miles of rock may explain why Bermuda seems to float above the surrounding ocean. When you purchase through links on our site, we may earn an affiliate commission. Here’s ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Structure Therapeutics ...

Changing the legal structure of a business is a pivotal moment in an entrepreneur’s journey, requiring both careful planning and a deep understanding of the potential legal, financial and operational ...

Department of Chemistry, University of Copenhagen, Universitetsparken 5, DK 2100 Copenhagen, Denmark Department of Chemistry, Technical University of Denmark, Kemitorvet 207, DK 2800 Kongens Lyngby, ...

Official support for free-threaded Python, and free-threaded improvements Python’s free-threaded build promises true parallelism for threads in Python programs by removing the Global Interpreter Lock ...

Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. GPCR's valuation appears attractive given a $1B ...